Starpharma today released its annual report and financial results for the year ended 30 June 2015.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2015.

The Australian's Sarah-Jane Tasker reports on Starpharma CEO Jackie Fairley's calls for simple changes to superannuation laws similar to those in the US and UK to incentivise individuals and funds to invest in companies like Starpharma and similar technology based companies, which would create a "paradigm shift in investment in the knowledge economy".

She said that "given biotech is a global industry Australia had to ensure there was an environment that encouraged smaller companies to develop into much larger companies and get to a more advanced commercial stage."

Go to the article (external link - paywall)

Tim Binstead reports that Starpharma has found star backers in well-known investment banker Mark Carnegie and property guru James Dack.

Go to the article (external link)

In the latest episode of Starpharma TV, CEO Dr Jackie Fairley and Jason Lickliter, Principal Investigator and Oncologist, Nucleus Network, Alfred Hospital, Melbourne, discuss Starpharma’s Phase 1 clinical trial of DEP™ docetaxel. They discuss the benefits of the drug compared to docetaxel and the positive initial results from the trial, with the dosage of the drug now exceeding the most commonly used dose for Taxotere® of 75mg/m2, with no dose limiting toxicities, including neutropenia, having been observed to date.

Go to the video (external link)

DEP (Dendrimer Enhanced Particle) technology improves drug availability, reduces toxicity; potential for repositioning $billion drugs.

Go to the article (external link)

The Herald Sun's John Beveridge highlights the benefits of Starpharma's drug delivery technology, but also notes that it is "not a one-trick-pony", with its phase 3 bacterial vaginosis trials and agrochemical opportunities.   

Go to the article (external link)

Starpharma today announced the signing of an extension to the existing collaboration agreement with AstraZeneca to commence scale up of a dendrimer enhanced oncology molecule (“DEP™ conjugate”) for further development.

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2015.

Starpharma today released an update to the progress of its phase 1 clinical trial of DEP™ docetaxel for advanced solid cancers. The DEP™ docetaxel dose level now exceeds the most commonly used dose for Taxotere^® of 75mg/m², with no dose limiting toxicities (DLT), including neutropenia, having been observed to date.